![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
VX-135 FOR THE TREATMENT OF CHRONIC HEPATITIS - In Vitro Safety/Potency/Mechanism
|
|
|
Reported by Jules Levin
APASL 2013 Singapore June 6-10
C Tan, H., Deval, J., Kang, H., Moy, C., Jin, Z., Jekle, A, *Rijnbrand R., *Kieffer, T., Blatt, L.M., Chanda, S.M., Dyatkina, N., Wang, G., Zhang, Q., Symons, J.A., Beigelman, L., Smith, D.B.
Alios BioPharma Incorporated, South San Francisco, CA, USA and *Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA
![APASL1.gif](../images/062513/062513-1/APASL1.gif)
![APASL2.gif](../images/062513/062513-1/APASL2.gif)
![APASL3.gif](../images/062513/062513-1/APASL3.gif)
![APASL4.gif](../images/062513/062513-1/APASL4.gif)
![APASL5.gif](../images/062513/062513-1/APASL5.gif)
![APASL6.gif](../images/062513/062513-1/APASL6.gif)
![APASL7.gif](../images/062513/062513-1/APASL7.gif)
![APASL8.gif](../images/062513/062513-1/APASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|